Diagonal Therapeutics is a biotechnology company developing disease-modifying clustering antibodies that repair dysregulated signaling implicated in a range of genetic and severe diseases. The company combines proprietary computational and experimental techniques through its DIAGONAL Product Engine to efficiently discover and optimize therapeutic antibody assets across hematology, hepatology, and nephrology, including the DIAG723 program for HHT and PAH.
Leadership & Board
Current Number of Employees41
Current LinkedIn Followers6,435
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$125M
Total Amount Raised$125M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$125M
Latest Funding Amount$125M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Diagonal Therapeutics had 41 employees as of September 21, 2026. The number of employees increased by 1 (2.50%) week-over-week.
41Latest Employee Count
1(2.50%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Diagonal Therapeutics had 6,435 followers as of September 21, 2026. The number of followers increased by 11 (0.17%) week-over-week.
6,435Latest Followers Count
11(0.17%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.